Zanthoamides G-I: Three New Alkamides from *Zanthoxylum zanthoxyloides*

Stephanie T. Guetchueng, Lutfun Nahar, Kenneth J. Ritchie, Fyaz M. D. Ismail, Andrew R. Evans and Satyajit D. Sarker*

Medicinal Chemistry and Natural Products Research Group, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Faculty of Science, James Parsons Building, Byrom Street, Liverpool L3 3AF, UK

*Corresponding author

Tel: +44-(0)1512312096; Fax: +44-(0)1512312170

E-mail address: S.Sarker@ljmu.ac.uk (S. D. Sarker)

ABSTRACT

Three new alkamides, zanthoamides G-I (**1**-**3**), together with ten known compounds, araliopsine, skimmianine, *N*-methylplatydesminium cation, isoplatydesmine, myrtopsine, atanine**,** *N*-methylatanine**,** sesamin**,** hesperetin and hesperidin, were isolated from the fruits of *Zanthoxylum zanthoxyloides*. Their structures were elucidated by spectroscopic means. All isolated compounds were assessed for their cytotoxicity against A549, MCF7, PC3 and PNT2 cell lines. Among the alkamides, only zanthoamide G (**1**) showed low level of cytotoxicity against MCF7 cells.

Keywords:
Zanthoxylum zanthoxyloides; Rutaceae; Cytotoxicity; Alkamides; Zanthoamides

1. Introduction

The genus *Zanthoxylum* L. (family- Rutaceae) consists of *ca.* 250 species of trees and shrubs, distributed throughout tropical and temperate regions of the world (Global Biodiversity Information Facility, 2017). In Africa, this genus is represented by 35 species, many of which are used as spices, edible fruits, medicinal plants and wood for construction (Chase et al., 1999; Seidemann et al., 2005; Matu, 2011). *Zanthoxylum zanthoxyloides* (Lam.) Zepern. & Timler (synonyms - *Fagara zanthoxyloides* Lam. and *Zanthoxylum senegalense* DC), one of the African *Zanthoxylum* species, is a small tree (6-8 m), which is widely cited in African traditional medicine. Different parts of the plant are traditionally used in the forms of infusion and decoction to treat diseases such as malaria, fever, sickle cell anemia, tuberculosis, paralysis, elephantiasis, toothache, venereal diseases, dysmenorrhea, abdominal pain, cough, tuberculosis, urinary disorders, cancers and arthritis (Odebeyi and Sofowora, 1979; Amvam et al., 1998). In Cameroon, a decoction from Z. *zanthoxyloides* fruits is used for the treatment of cancers, sickle cell anemia and as a spice to cook special potages used as a purgative (Adjanohounet al., 1986; Tchiegang and Mbougueng, 2005). Previous phytochemical studies on the fruits revealed the presence of quinic acid derivatives and acridone alkaloids with aromatase properties (Ouattara et al., 2009; Wouatsa et al., 2013). Antifungal and antioxidant isobutylamides and cytotoxic benzophenanthridine alkaloids were reported from the roots (Sofowora et al., 1975; Chaaib et al., 2003; Adesina, 2005; Queiros et al., 2006). Other previously isolated compounds from the plant include aporphine and quinoline alkaloids, coumarins, lignans and various phenolic compounds (Adesina, 2005). In this paper, in continuation of our studies on Cameroonian medicinal plants (Wansi et al., 2016; Guetchueng et al., 2017, 2018; Tahsin et al., 2017), we now report on the isolation and identification of three new alkamides, zanthoamides G-I (**1**-**3**), together with ten known compounds (**4**-**13**) from the fruits of *Z. zanthoxyloides*, collected from Cameroon, and assessment of their cytotoxicity against three human cancer cell lines, adenocarcinomic alveolar basal epithelial (A549), breast adenocarcinoma (MCF7) and prostate cancer (PC3) and the normal human prostate epithelium (PNT2) cell lines.

2. Results and discussion

Reversed-phase preparative HPLC purification of the methanolic extract of the fruits of *Z. zanthoxyloides* afforded three new alkamides, named zanthoamides G-I (**1-3**), along with ten known compounds including: eight quinoline alkaloids, araliopsine (**4**), skimmianine (**5**), *N*-methylplatydesminium cation (**6**), isoplatydesmine (**7**), myrtopsine (**8**), atanine (**9**) and *N*-methylatanine (**10**), a lignan, sesamin (**11**) and two flavanones, hesperetin (**12**) and hesperidin (**13**) (Fig. 1). Whilst the new compounds were identified by extensive 1D and 2D NMR and HRMS analyses, the known compounds were identified by comparison of their spectroscopic data with respective literature data (Brown et al., 1980; Ngadjui et al., 1988; Liu et al., 2000; El-Shafae, 2002; Albarici et al., 2010; Haque et al., 2013).

Compounds **1-3** were obtained as white viscous liquids. The molecular formula of compound **1** was determined as $C_{18}H_{29}NO_4$ by HRESIMS from the *pseudo*molecular ion at *m/z* 346.1984, calculated 346.1989 for its sodium adduct $[M + Na]^+$ ($C_{18}H_{29}NO_4Na$). The ^1H NMR spectrum of **1** (Table 1) exhibited 14 signals corresponding to 24 protons including the signals of the proton of a secondary amine at 8.56 (1H, br s), six olefinic protons at δ7.12 (1H, dd, *J* = 10.4, 15.1), 6.60 (1H, dd, *J* = 11.1, 15.1), 6.27 (1H, dd, *J* = 10.8, 15.1), δ5.99 (1H, d, *J* = 15.0), 5.70 (1H, dd, *J* = 6.4, 15.0) and 5.44 (1H, m, *J* = 7.4), signals at δ1.18 (6H, s) and 1.11 (3H, d, *J* = 6.3) for three methyls, two oxygenated methines at δ3.58 (1H, m, *J* = 6.3) and 3.91 (1H, dd, *J* = 6.4, 12.9) and three methylene signals including a broad singlet at δ3.27 and two double doublets at δ2.29 (*J* = 7.0, 13.2) and 2.35 (*J* = 7.3, 14.8). Overlapping signals occurring between δ6.0-6.15 ppm resulting from two olefinic protons resonances were also observed. The ^{13}C NMR spectrum (Table 1) revealed signals for 18 carbons attributable to three methyls (δ27.2 x 2, δ18.8), three methylenes with one appearing relatively downfield at δ51.1, ten methines including two oxymethines at δ77.8 and 71.7, eight olefinic methines at δ143.0, 142.3, 134.0, 131.7, 130.2, 129.9, 128.2 and 123.2, and two quaternary carbons including an amide at δ169.4 and an oxygenated quaternary carbon at δ71.6. The assignment of the carbon signals was consistent with the resonances observed in the ^1H NMR experiment as well as the ^1J ^1H-^{13}C correlations observed in the HSQC-DEPTQ spectrum. In the ^1H-^1H COSY spectrum, a chain of vicinal correlations observed from H-2 to H-14 (Fig. 2), which helped to construct one part of the compound structure as CH_3-CH=CH-CH=CH-CH_2-CH_2-CH=CH-CH=CH-. In the HMBC spectrum, correlations from δ1.18 (H-3' and H-4') to carbon signals at δ51.1 (C-1'), 71.6 (C-2') and 27.2 (C3' or C-4'), and from δ 3.27 (s, H-1') to C-2', C-3' and C-4' identified the other part of the molecule as 2-hydroxy-isobutyl moiety. Further correlations in the HMBC

spectrum from H-1' (δ3.27), H-2 (δ5.99) and H-3 (δ7.12) to C-1 (δ169.4), in addition to the appearance of the methylene of the isobutyl moiety at δ55.1, established that the 2-hydroxy-isobutyl moiety was linked to the nitrogen of the amide group and the aliphatic moiety to the carbonyl of the amide. The geometry of the double bond C2/C3 was deduced as *trans* ($J_{H2/H3}$= 15.0 Hz) like those of C4/C5, C8/C9 and C10/C11. Compound **1** did not show any optical activity suggesting that it was obtained as a racemic mixture. Thus compound **1** was identified as (12*RS*, 13*RS*)-(2*E*, 4*E*, 8*E*, 10*E*)-*N*-(2-hydroxy-2-methylpropyl)-12,13-dihydroxy-2,4,8,10-tetradecatetraenamide, given the trivial name zanthoamide G (**1**). The structure of zanthoamide E (**1**) resembled that of zanthoamide C isolated from *Zanthoxylum bungeanum* (Wang et al., 2016) with the only difference being the additional olefinic bond between C3 and C6 present in **1**. Furthermore, the structure of **1** was supported by the fragmentation pattern observed in the EIMS experiment. The peaks corresponding to $[M\text{-}C_2H_5O]^+$ and $[M\text{-}H_2O\text{-}C_2H_5O]^+$ could be attributed to the loss of the hydroxylated fragments on the aliphatic side on the molecule while peaks matching $[M\text{-}CH_3]^+$, $[M\text{-}H_2O]^+$ and $[M\text{-}C_2H_6]^+$ could be characteristic for the loss of fragments on the 2-hydroxy-isobutyl moiety.

The molecular formula of compound **2** was determined as $C_{18}H_{29}NO_4$ from its HRESIMS spectrum, where a *pseudo*molecular ion was observed as at *m/z* 346.1992 $[M + Na]^+$ (calculated 346.1989 for $C_{18}H_{29}NO_4Na$). The ^1H and ^{13}C NMR spectra (Table 1) of **2** established it as an aliphatic amide, similar to **1**, with the only difference being the placement of the oxymethines, which were not adjacent to each other like in **1**. A ^1H-^1H COSY spectrum revealed scaler couplings between oxymethine at δ4.28 (H-13) and methyl at δ1.20 (H-14) and also with the olefinic proton at δ5.73 (H-12), and the correlation from the other oxymethine at δ4.10 (H-8) to the methylene at δ1.60 (H-7) and the olefinic proton at δ5.68 (H-9) (Fig. 2). These correlations could be further confirmed from the HMBC spectrum, where correlations from H-8 to C-6 (δ29.9), C-7 (δ37.4) and C-9 (δ137.0), and from H-13 to C-12 (δ138.6) and C-14 (δ23.5) were observed (Fig. 2). The geometry of the olefinic bonds were confirmed as *trans* from relevant coupling constants ($J_{H2/H3}$= 15.1, $J_{H4/H5}$= 15.2, $J_{H9/H10}$= 14.6 and $J_{H11/H12}$= 14.5). Compound **2** was optically inactive suggesting that it was a racemic mixture. Thus, compound **2** was identified as (8*RS*, 13*RS*)-(2*E*, 4*E*, 9*E*, 11*E*)-*N*-(2-hydroxy-2-methylpropyl)-8,13-dihydroxy-2,4,9,11-tetradecatetraenamide, and given the trivial name, zanthoamide H (**2**). The structure of zanthomide H (**2**) is quite similar to that of zanthoamide B isolated from *Z. bungeanum* (Wang et al., 2016) with the only difference being the hydroxyl groups are in positions 8 and 13 in **2**, whilst in zanthoamide B, they are in positions 6 and 13. It should be

noted that in the published paper (Wang et al., 2016) the IUPAC name given to zanthoamide B was erroneous and should be reviewed to (6*RS*, 13*RS*)-(2*E*, 4*E*, 9*E*, 11*E*)-*N*-(2-hydroxy-2-methylpropyl)-6,13-dihydroxy-2,4,9,11-tetradecatetraenamide to comply with the corresponding discussion and published spectroscopic data supporting the two –OH groups in that molecule to be in positions 6 and 13.

Compound **3** has a molecular formula of $C_{18}H_{27}NO_4$, determined from the *pseudo*molecular ion $[M + H]^+$ observed at *m/z* 322.2017 in its HRESIMS (calculated 322.2013 for $C_{18}H_{28}NO_4$). ^1H and ^{13}C NMR data (Table 1) of **3** indicated that like **1** and **2**, it was also an aliphatic amide, and there were spectral similarities with compound **2**, with the obvious difference being the absence of the C-8 hydroxyl group as observed in **2**, and the presence of a ketone group in **3** instead, which was confirmed by the signal at δ202.0 in the ^{13}C NMR spectrum (Table 1). The position of the ketone group was confirmed from the HMBC experiment, where correlations were observed between the ketone carbonyl carbon (δ202.0) and the protons at δ2.48 (H-6), 6.21 (H-9), 2.79 (H-7) and 7.29 (H-10) (Fig. 2). This was also supported by the downfield shifts of C-10 and C-12 from δ129.8 and 138.6 in **2** to δ144.5 and 149.3, respectively, in **3**, caused by the presence of a ketone group nearby. The geometry of the double bonds C2/C3, C4/C5, C9/C10 and C11/C12 was determined as *trans* from the relevant coupling constants, *J* = 15.0, 15.0, 15.6 and 15.1, respectively. Unlike compounds **1** and **2**, compound **3** was found to be optically active, $[\alpha]_D^{25}$ = -25.6. However, the absolute configuration could not be determined because of paucity of this sample. Thus, compound **3** was identified as (13*)-(2*E*, 4*E*, 9*E*, 11*E*)-*N*-(2-hydroxy-2-methylpropyl)-13-hydroxy-2,4,9,11-tetradecatetraenamide and given the trivial name, zanthoamide I (**3**).

This is the first report on the occurrence of compounds **4**, **6**-**8** and **10,** in addition to three new alkamides (**1**-**3**), in *Z. zanthoxyloides*. Several alkamides with structures similar to zanthoamides G-I (**1**-**3**) were previously reported in several *Zanthoxylum* species including *Z. achtoum, Z. ailanthoides, Z. armatum, Z. bungeanum, Z. heitzii, Z. integrifoliolum, Z. piperitum, Z. schinifolium, Z. syncarpum, Z. tessmannii* and *Z. zanthoxyloides* (Ross et al., 2005; Wang et al., 2016; Chruma et al., 2018). Araliopsine (**4**) was previously isolated from *Z. simulans* (Chang et al., 1981), *N*-methylplatydesminium catium (**6**) from *Z. usambarense* and *Z. chalybeum* (Kato et al., 1996), isoplatydesmine (**7**) from *Z. nididum* (Ishikawa et al., 1995), myrtopsine (**8**) from *Z. integrifoliolum* (Ishii et al., 1982) and *N*-methylatanine (**10**) from *Z. beecheyanum* (Cheng et al., 2004) and *Z. rigidum* (Moccelini et al., 2009).

Compounds **1-13** were evaluated for their cytotoxicity against A549 (adenocarcinomic human alveolar basal epithelial), MCF7 (human breast adenocarcinoma), PC3 (human prostate cancer) and PNT2 (human normal prostate epithelium) cells (Table 2). Among the tested compounds, hesperidin (**13**) showed a moderate level of cytotoxicity against A549, MCF7 and PC3 cells with IC_{50} values of 29.5±7.5, 74.2±17.8 and 51.7±8.7 μM, respectively, with the IC_{50} value for the normal cell line (PNT2) being 129.0±20.3 μM**.** Skimmianine (**5**) and sesamin (**11**) were moderately active against MCF7 and PC3 cells, exhibiting IC_{50} values of 53.7±09.5 and 33.4±9.8 μM, respectively. None of the isolated new compounds (**1**-**3**) was particularly cytotoxic against the cell lines at the test concentrations (0-200 μM). However, only zanthoamide G (**1**) showed some cytotoxicity against MCF7 cells (IC_{50} = 153.6±32.7μM). Several alkamides isolated from the *Zanthoxylum* genus have been found to possess weak or moderate cytotoxicity (Devkota et al., 2012; Wang et al., 2017). Additionally, alkamides possess antidiabetic, anti-inflammatory, immunomodulatory and nerve growth factor potentiating properties (Greger, 2016; Tian et al., 2016; Wang et al., 2017).

3. Materials and methods

3.1. General experimental procedures

Analytical and preparative TLC were carried out on 0.2 mm Sigel 60 F_{254} plates (Merck, Germany). Spots were visualized under short (254 nm) and long wavelength (366 nm), and also by spraying with a 1% anisaldehyde solution in aqueous H_2SO_4 followed by heating to 105°C for 5 min. The NMR spectroscopic analyses were performed in CD_3OD or $CDCl_3$ solution on a Bruker AMX300 instrument (300 MHz for ^1H and 75 MHz for ^{13}C) or Bruker AMX600 NMR spectrometer (600 MHz for ^1H and 150 MHz for ^{13}C). HRESIMS analyses were performed on a Xevo G2-S ASAP or LTQ Orbitrap XL1 spectrophotometer. EIMS analysis was recorded on a Finnigan MAT 95 spectrometer. Analytical HPLC was performed on a Dionex UPLC 3000 (Thermoscientific, UK) HPLC coupled with a photo-diode-array (PDA) detector (Thermoscientific). Extracts and fractions were analyzed on a Phenomenex C_{18} column (150 × 4.6 mm, 5 μm, Phenomenex, USA). An Agilent 1200 Infinity series preparative HPLC system coupled with a PDA detector (Agilent, UK) was used to isolate compounds; a Hichrom ACE C18 preparative column (150 × 21.2 mm, 5 μm) was used . The column temperature was set at 25 °C. The chromatogram was monitor at variable UV–vis wavelengths

(215, 254, 280 and 320 nm). Optical rotation was determined using Bellingham-Stanley ADP660 polarimeter (MeOH, c in g/100mL). UV spectra were recorded on Analytik Jena Specord 210 spectrophotometer. IR was recorded on an Agilent Cary 630 FT-IR.

3.2. Plant material

The fruits of *Z. zanthoxyloides* were collected from Dschang local market, Western Region, Cameroon, in November 2015, and identified by Mr Victor Nana, a taxonomist at the Cameroon National Herbarium, by comparing the plant sample with the voucher specimen 21793/SFR/CAM.

3.3. Extraction and isolation of compounds

The air-dried ground fruits (350.0 g) of *Z. zanthoxyloides* were Soxhlet-extracted, successively, with *n*-hexane, DCM and MeOH (800 mL, 10 cycles each). After evaporation at 40^{o}C under reduced pressure, 34.6 g, 3.9 g and 19.6 g of *n*-hexane, DCM and MeOH extracts were obtained, respectively. A portion of the dried MeOH extract (2 g) was suspended in 10 mL of 10% MeOH- water and loaded on to a Strata C-18-E cartridge (Phenomenex, USA) (20 g), previously washed with MeOH (50 mL), followed by equilibration with water (100 mL). The cartridge was eluted with MeOH–water mixture of decreasing polarity to obtain four fractions: 20, 50, 80 and 100% MeOH in water (200 mL each) (F1-F4, respectively). All fractions were concentrated to dryness using a combination of rotary evaporator and freeze-dryer and stored at 4^{o}C until further use. F3 (845.8 mg) was subjected to preparative HPLC using an ACE prep-column (150 × 21.2 mm, Hichrom Ltd, UK), flow rate 10 mL/min, mobile phase gradient of water (A) and methanol (B) both containing 0.1% TFA: 30-100% B, 0-30 min; 100% B, 30-35 min; 100-30% B, 35-40 min, monitored at wavelengths 254 and 280 nm to yield *N*-methylplatydesmine cation (12.1 mg) (**6**), myrtopsine (2.3 mg) (**8**), hesperidin (1.8 mg) (**12**), hesperetin (2.4 mg) (**12**), skimmianine (7.8 mg) (**5**), atanine (3.3 mg) (**9**), N-methylatanine (2.8 mg) (**10**) and sesamin (4.5 mg) (**11**) having the retention times (t_R) 3.2, 7.5, 19.2, 24.8, 25.7, 29.3, 30.8 and 31.9 min, respectively.

F2 (704.8 mg) was also analyzed by preparative HPLC as above, but with a different mobile phase: a gradient of water containing 0.1% TFA (A) and acetonitrile (B): 30-100% B over 30 min and monitor at wavelengths 254 and 280 nm to yield *N*-methylplatydesmine cation (3.5 mg) (**6**) and isoplatydesmine (3.6 mg) (**7**) having the retention times (t_R) 3.1 and 5.3 min,

respectively. Fraction F2-B (5.7 mg) collected at t_R = 4.8 min was further purified through preparative TLC to afford **2** (3.2 mg, EtOAc-MeOH 70:30, R_f 0.41). Fraction F2-D (3.6 mg) collected at t_R = 5.5 min was also purified by preparative TLC to obtain **3** (1.9 mg, EtOAc-MeOH 70:30, R_f 0.46). Preparative TLC of fraction F2-E (3.8 mg) collected at t_R = 6.2 min provided **1** (1.8 mg, EtOAc-MeOH 70:35, R_f 0.41). Purification of fraction F2-F (10.2 mg) collected at t_R = 6.5 min using TLC with a mixture of EtOAc-MeOH (70:35) as eluent afforded more of **1** (2.5 mg, R_f 0.41) and ariolipsine **4** (3.6 mg, R_f 0.28).

*3.4. Zanthoamide G (**1**)*

White viscous liquid; $[\alpha]_D^{25}$ +0.0 (c 0.004, MeOH); UV λ_{max} (nm): 236, 260; FT-IR (ATR) ν_{max} (cm^{-1}): 3380, 2920, 2850, 1580; HRESIMS *m/z* 346.1984 $[M + Na]^+$ (calc 346,1989 for $C_{18}H_{29}NO_4Na$,); EIMS *m/z* (rel. int.): 278 (100) $[M\text{-}C_2H_5O]^+$, 260 (95) $[M\text{-}H_2O\text{-}C_2H_5O]^+$, 293 (5) $[M\text{-}2xCH_3]^+$, 305 (5) $[M\text{-}H_2O]^+$, 308 (2) $[M\text{-}CH_3]^+$; see Table 1 for ^{1}H NMR (600 MHz, CD_3OD) and ^{13}C NMR (150 MHz, CD_3OD) data.

*3.5. Zanthoamide H (**2**)*

White viscous liquid; $[\alpha]_D^{25}$ +0.0 (c 0.006, MeOH); UV λ_{max} (nm): 232, 262; FT-IR (ATR) ν_{max} (cm^{-1}): 3325, 2950, 2920, 2840, 1680, 1600, 1535; HRESIMS *m/z* 346.1992 $[M + Na]^+$ (calc 346,1989 for $C_{18}H_{29}NO_4Na$); EIMS *m/z* (rel. int.): 323 (10) $[M]^+$, 306 (11) $[M+H\text{-}H_2O]^+$, 263 (27) $[M\text{-}C_3H_6O]^+$, 183 (45) $[M+H\text{-}C_8H_{13}O_2]^+$, 165 (65) $[M+H\text{-}H_2O\text{-}C_8H_{13}O_2]^+$; see Table 1 for ^{1}H NMR (600 MHz, CD_3OD) and ^{13}C NMR (150 MHz, CD_3OD) data.

*3.6. Zanthoamide I (**3**)*

White viscous liquid; $[\alpha]_D^{25}$ – 25.6 (c 0.013, MeOH); UV λ_{max} (nm): 214, 264; FT-IR (ATR) ν_{max} (cm^{-1}): 3380, 2920, 2860, 2920, 2850, 1680, 1620, 1550, 980; HRESIMS *m/z* 322.2017 $[M+H]^+$ (calc 322.2013 for $C_{18}H_{28}NO_4$); EIMS *m/z* (rel. int.): 321 (15) $[M]^+$, 303 (17) $[M\text{-}H_2O]^+$, 273 (20) $[M\text{-}C_2H_5O]^+$, 263 (90) $[M\text{-}C_3H_6O]^+$; see Table 1 for ^{1}H NMR (600 MHz, CD_3OD) and ^{13}C NMR (150 MHz, CD_3OD) data.

3.7. Cytotoxicity assay

The *in vitro* antiproliferative (cytotoxic) activity of all the isolated compounds (**1**-**13**) from *Z. zanthoxyloides* was assessed against A549, MCF7 and PC3 human cancer cell lines, and also against normal prostate epithelium cells (PNT2). The cell lines were grown in RPMI medium supplemented with L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100

μg/mL) and 10% fetal bovine serum (FBS). The cells were cultured at 37°C, 5% CO_2 and 95% humidity and were seeded into 96 wells plate (1.2×10^4/well) and incubated for 24h. The cells were then treated for 48h with the isolated compounds (0 to 200 μM) before the cell viability was assessed using the MTT assay (Mosmann, 1983). To achieve this, the medium in each well was replaced by MTT solution (500 μg/mL in medium) and incubated for 2h. The toxicity of the compounds was assessed by the ability of the cells to reduce the yellow MTT dye to blue formazan crystals. The formazan crystals formed were dissolved in DMSO and optical density was read at 570 nm in a ClarioStar plate reader. Three individual wells were assayed per treatment; the assay was repeated three times and cytotoxic activity was determined as percentage of control cells [(absorbance of treated cells/absorbance of untreated cells) × 100]. Doxorubicin was used as positive control and the IC_{50} value of each test sample was calculated using the software Graphad Prism 7.02.

Acknowledgments

Mass spectrometry data were acquired at the EPSRC UK National Mass Spectrometry Service (NMSS) at Swansea University. We thank the Commonwealth Commission for the award of a PhD scholarship to S. T. G.

Appendix A. supplementary data

NMR and MS spectra of zanthoamides G-I (**1**-**3**).

References

Adesina, S. K., 2005. Further novel constituents of *Zanthoxylum zanthoxyloides* root and pericarp. Afr. J. Trad. Comp. Alt. Med. 2, 282-301.

Adjanohoun, E. J., Ahyi, M. R. A., Ake, A. L., Akpagna, K., Chibon, P., Watora, E-H. A., Eyme, J., Garba, M., Gassita, J. N., Gbeasor, M., Goudote, E., Guinko, S., Hodouto, K. K., Hougnon, P., Keita, A., Keoula, Y., Kluga-Ocloo, W. P., Lo, I., Siamevi, K. M., Taffame, H. Y., 1986. Médecine traditionnelle et pharmacopée: contributionaux études ethnobotaniques et floristiques auTogo. A. C. C. T: Paris.

Albarici, T. R., Vieira, P. C., Fernandes, J. B., Silva, M. F. G., Pirani, J. R., 2010. Cumarinas e alcaloides de *Rauia resinosa* (Rutaceae). Quim. Nova. 33, 2130-2134.

Amvam, Z. P. H., Biyiti, L., Tchoumbougnang, F., Menut, C., Lamaty, G., Bouchet, P. H., 1998. Aromatic plants of tropical central Africa. Part XXX II Chemical composition and antifungal activity of thirteen essentials oils from aromatic plants of Cameroon. Flav. Frag. J. 13, 107-114.

Brown, N. M. D., Grundon, M. F., Harrison, D. M., Surgenor, S. A., 1980. The ^{13}C NMR spectra of hemi-terpenoid quinoline alkaloids and related prenylquinolines. Tetrahedron 36, 3579-3584.

Chaaib, F., Quieroz, E. F., Ndjoko, K., Diallo, D., Hostettmann, K., 2003. Antifungal and antioxidant compounds from the root bark of *Fagara zanthoxyloides*. Planta Med. 69, 316-320.

Chang, Z. Q., Liu, F., Wang, S. L., Zhao, T. Z., Wang, M.T., 1981. Studies on the chemical constituents of *Zanthoxylum simulans* Hance. Yaoxue Xuebao 16, 394-396.

Chase, M. W., Morton, C. M., Kallunki, J. A., 1999. Phylogenetic Relationships of Rutaceae: a Cladistic Analysis of the Subfamilies Using Evidence from rbcL and atpB Sequence Variation. Am. J. Bot. 86, 1191-1199.

Cheng, M. J., Wu, C. C., Tsai, A. L., Chen, I. S., 2004. Chemical and antiplatelet constituents from the stem of *Zanthoxylum beecheyanum*. J. Chin. Chem. Soc. 51, 1065-1072

Chruma, J. J., Cullen, D. J., Bowman, L. T., Patrick, H., 2018. Polyunsaturated fatty acid amides from the *Zanthoxylum* genus - from culinary curiosities to probes for chemical biology. Nat. Prod. Rep. 35, 54-74.

Devkota, K. P., Wilson, J., Henrich, C. J., McMahon, J. B., Reilly, K. M., Beutler, J. A., 2012. Isobutylhydroxyamides from the pericarp of Nepalese *Zanthoxylum armatum* inhibit NF1-defective tumor cell line growth. J. Nat. Prod. 76, 59-63.

El-Shafae, A. M., 2002. Bioactive polymethoxyflavones and flavanone glycosides from the peels of *Citrus deliciosa* Ten. Chin. Pharm. J. 54, 199-206.

Global Biodiversity Information Facility: Biodiversity occurrence data, In: GBIF Data Portal. December 17, 2017, Available from: http://data.gbif.org/species/.

Greger, H., 2016. Alkamides: a critical reconsideration of a multifunctional class of unsaturated fatty acid amides. Phytochem. Rev. 15, 729-770.

Guetchueng, S. T., Nahar, L., Ritchie, K. J., Ismail, F. M. D., Wansi, J. D., Evans, A. R., Sarker, S. D., 2017. Kaurane diterpenes from the fruits of *Zanthoxylum leprieurii* (Rutaceae). Rec. Nat. Prod. 11, 304-309.

Guetchueng, S. T., Nahar, L., Ritchie, K. J., Ismail, F. M. D., Evans, A. R., Sarker, S. D**.** , 2018. *ent*-Clerodane diterpenes from the bark of *Croton oligandrum* Pierre *ex.* Hutch. and assessment of their cytotoxicity against human cancer cell lines. Molecules (in press).

Haque, M. M., Begum, S., Sohrab, M. H., Ahsan, M., Hasan, C. M., Ahmed, N., Haque, R., 2013. Secondary metabolites from the stem of *Ravenia spectabilis* Lindl. Pharmacogn Magazine 9, 76-80.

Ishii, H., Chen, I.-S., Akaike, M., Ishikawa, T., Lu, S. T., 1982. Studies on the chemical constituents of rutaceous plants. XLIV. The chemical constituents of *Xanthoxylum integrifoliolum* (Merr.) Merr. (*Fagara integrifoliola* Merr.). 1. The chemical constituents of the root wood. Yakugaku Zasshi 102, 182-195.

Ishikawa, T., Seki, M., Nishigaya, K., Miura, Y., Seki, H., Chen, I.-S., Ishii, H., 1995. Studies on the chemical constituents of *Xanthoxylum nitidum* (Roxb.) D. C. (*Fagara nitida* Roxb.). III. The chemical constituents of the wood. Chemi. Pharma. Bull. 43, 2014-2018.

Kato, A., Moriyasu, M., Ichimaru, M., Nishiyama, Y. D. F., Nganga, J. N., Mathenge, S. G., Ogeto, J. O., 1996. Isolation of Alkaloidal Constituents of *Zanthoxylum usambarense* and *Zanthoxylum chalybeum* Using Ion-Pair HPLC. J. Nat. Prod. 59, 316-318.

Liu, S. L., Tsai, I. L., Ishikawa, T., Harayama, T., Chen, I. S., 2000. , Bishordeninyl terpene alkaloids from *Zanthoxylum integrifoliolum.* J. Chin. Chem. Soc. 47, 571-574.

Matu, E. N., 2011. *Zanthoxylum zanthoxyloides* (Lam.) Zepern. & Timler. In PROTA (Plant Resources of Tropical Africa/Ressources végétales de l'Afrique tropicale). Edited by Schmelzer GH, Gurib-Fakim A. Wageningen: Internet record from Protabase.

Moccelini, S. K., da Silva, V. C., Ndiaye, E. A., De Sousa Jr., P. T., Vieira, P. C., 2009. Phytochemical study from root barks of *Zanthoxylum rigidum* Humb. & Bonpl. ex Willd (Rutaceae). Quim. Nova 32, 131-133.

Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65, 55-63.

Ngadjui, B. T., Ayafor, J. F., Sondengam, B. L., 1988. Further alkaloids of *Araliopsis tabouensis*: the structure of araliopsinine and the presence of dimeric 2-quinoline alkaloids. Bull. Chem. Soc. Eth. 2, 21-28.

Odebiyi, O. O., Sofowora, E. A., 1979. Antimicrobial alkaloids from a Nigerian chewing stick (*Fagara zanthoxyloides*). Planta Med. 36, 204-207.

Ouattara, B., Jansen, O., Angenot, L., Guissou, I. P., Frederich, M., Fondu, P., Tits, M., 2009. Anti-sickling properties of divanilloylquinic acids isolated from *Fagara zanthoxyloides* Lam. (Rutaceae). Phytomed. 16, 125-129.

Queiros, E. F., Hay, A-E., Chaaib, F., Van Diemen, D., Diallo, D., Hostettmann, K., 2006. Hostettmann, New and bioactive aromatic compounds from *Zanthoxylum zanthoxyloides.* Planta Med. 72, 746-750.

Ross, S. A., Al-Azeib, M. A., Krishnaveni, K. S., Fronczek, F. R., Burandt, C. L., 2005. Alkamides from the leaves of *Zanthoxylum syncarpum*. J. Nat. Prod. 68, 1297-1299.

Seidemann, J., 2005. World Spice Plants: Economic Usage, Botany, Taxonomy. Springer-Verlag: Berlin, p. 399-402.

Sofowora, E. A., Isaac-Sodeye, W. A., Ogunkoya, L. O., 1975. Isolation and characterization of an antisickling agent from *Fagara zanthoxyloides* root. Lloydia. 38, 169-174.

Tahsin, T., Wansi, J. D., Al-Groshi, A., Evans, A., Nahar, L., Martin, C., Sarker, S. D., 2017. Cytotoxic properties of the stem bark of *Citrus reticulata* Blanco (Rutaceae). Phytotherapy Res. 31, 1215-1219.

Tchiegang, C., Mbougueng, P. D., 2005. Composition chimique des épices utilisées dans la préparation du Nah-poh et du Nkui de l'ouest Cameroun. Tropicultura 23, 193-200.

Tian, J. M., Wang, Y., Xu, Y. Z., Yu, Z. C., Wei, A. Z., Zhang, W. M., Gao, J. M. 2016. Characterization of isobutylhydroxyamides with NGF-potentiating activity from *Zanthoxylum bungeanum*. Bioorg. Med. Chem. Lett. 26, 338-342.

Wouatsa, N. A.V., Misra, L., Shiv, K., Prakash, O., Khan, F., Tchoumbougnang, F., Venkatesh, K. R., 2013. Aromatase and glycosyl transferase inhibiting acridone alkaloids from fruits of Cameroonian *Zanthoxylum* species. Chem. Cent. J. 7, 125-139.

Wang, Y., Li, C.H., Luo, B., Sun, Y.N., Kim, Y.H., Wei, A. Z., Gao, J. M., 2016. Isobutylhydroxyamides from *Zanthoxylum bungeanum* and their suppression of NO production. Molecules 21, 1416-1424.

Wang, Y., Liao, Z. B., Cao, R., Li, H., Wei, A. Z., Gao, J. M. 2017. Isolation, Structural Characterization and Neurotrophic Activity of Alkylamides from *Zanthoxylum bungeanum.* Nat. Prod. Comm. 12, 1121-1124.

Wansi, J. D., Alain, T. T., Toze, F. A. A., Nahar, L., Martin, C., Sarker, S. D., 2016. Cytotoxic acridone and indoloquinazoline alkaloids from *Zanthoxylum poggei*. Phytochemistry Lett. 17, 293-298.



Fig. 1. Structures of zanthoamides G-I (**1**–**3**)



Fig. 2. ^{1}H-^{1}H COSY and some key HMBC correlations of zanthoamide G-I (**1-3**)

Table 1.

^{1}H (600 MHz) and ^{13}C (150 MHz) NMR data of zanthoamides G-I (**1**-**3**)[a]

Position	Chemical shift δ in ppm					
	^{1}H (*J* in Hz)			^{13}C		
	1	**2**	**3**	**1**	**2**	**3**
1	-	-	-	169.4	169.5	169.4
2	5.99 d (15.0)	6.01 d (15.1)	6.01 d (15.0)	123.2	123.1	123.5
3	7.12 dd (10.4, 15.1)	7.15 dd (10.7, 15.0)	7.13 dd (10.7, 15.1)	142.3	142.4	142.1
4	6.27 dd (10.8, 15.1)	6.25 dd (10.7, 15.2)	6.26 m	130.2	130.1	130.4
5	6.11 m	6.14 m	6.13 dt (7.0, 15.0)	143.0	143.4	142.2
6	2.29 dd (7.0, 13.2)	2.20 m	2.48 dd (7.2, 14.1)	33.9	29.9	28.4
7	2.35 dd (7.3, 14.8)	1.60 m	2.79 dd (7.2, 14.5)	28.0	37.4	39.9
8	5.44 dd (7.2, 15.1)	4.10 q (6.5, 13.0)	-	131.7	72.4	202.0
9	6.07 m	5.68 dd (6.7, 14.6)	6.21 d (15.6)	129.9	137.0	130.2
10	6.60 dd (11.1, 15.1)	6.20 m	7.29 dd (10.8, 15.6)	128.2	129.8	144.5
11	5.70 dd (6.4, 15.0)	6.20 m	6.42 dd (10.3, 15.1)	134.0	131.0	128.0
12	3.91 dd (6.4, 12.9)	5.73 m	6.31 m	77.8	138.6	149.3
13	3.58 m	4.28 q (6.3, 12.5)	4.38 m	71.7	68.8	68.4
14	1.11 d (6.3)	1.20 d (6.4)	1.22 d (6.5)	18.8	23.5	23.1
1’	3.27 s	3.28 s	3.27 s	51.1	51.1	51.1
2’	-	-	-	71.6	71.6	71.5
3’	1.18 s	1.19 s	1.18 s	27.2	27.2	27.2
4’	1.18 s	1.19 s	1.18 s	27.2	27.2	27.2
NH	8.56 br s	8.56 br s	8.56 br s	-	-	-

[a]Spectra obtained in CD_3OD, and DEPTQ, COSY, HSQC and HMBC experiments confirmed assignment of all ^{1}H and ^{13}C signals

Table 2

Cell Growth Inhibitory Activities (IC_{50} in μM) of Isolated Compounds against Cancer (A549, MCF7, PC3) and Normal (PNT2) Cells*

Compounds	IC_{50} values in μM			
	A549	MCF7	PC3	PNT2
1	>200	153.6±32.7	>200	>200
2	>200	>200	>200	181.6±35.7
3	>200	>200	>200	>200
4	>200	>200	>200	>200
5	113.4±15.8	53.7±09.5	164.7±21.3	104.4±16.2
6	>200	152.2±33.6	>200	>200
7	>200	172.2±31.4	>200	>200
8	>200	>200	>200	>200
9	112.0±17.4	>200	195.3±22.6	>200
10	114.7±18.2	142.5±17.0	>200	>200
11	108.5±22.1	>200	33.4±9.8	>200
12	151.4±25.4	>200	159.7±28.5	>200
13	29.5±7.5	74.2±17.8	51.7±8.7	129.0±20.3
Doxorubicin	1.3±0.3	0.7±0.1	16.4±2.9	1.5±0.3

*Data are represented as mean ± SEM (n = 3); IC_{50} = sample concentration that caused 50% cell growth inhibition